From: A review of outcome following valve surgery for rheumatic heart disease in Australia
 | All | RHD-related | Non-RHD | P value |
---|---|---|---|---|
 | N = 17227 | N = 1384 | N = 15843 |  |
Age (years) (median (IQRa) | 71.3(61.2 – 78.3) | 59.7(50.9 – 71.4) | 71.9(62.3 – 78.6) | <0.001 |
Sex (% female) (95 % CI#) | 37.3(36.6 – 38.1) | 64.5(61.9 – 67.0) | 35.0(34.2 – 35.7) | <0.001 |
Indigenous status (% Aboriginal and Torres Strait Islander people) (95 % CI) | 1.9(1.7 – 2.1) | 12.6(10.9 – 14.4) | 1.0(0.8 – 1.2) | <0.001 |
Concomitant CABG (%, 95 % CI) | 39.1(38.4 – 39.8) | 21.2(19.1 – 23.5) | 40.7(39.9 – 41.4) | <0.001 |
Pre-operative comorbidities | ||||
 Diabetes (%, 95 % CI) | 23.2(22.5 – 23.8) | 20.3(18.2 – 22.5) | 23.4(22.8 – 24.1) | 0.009 |
 Chronic kidney disease (% eGFR < 60 mL/min/1.73 m2) (95 % CI)) | 36.7(36.0 – 37.5) | 31.2(28.8 – 33.7) | 37.2(36.5 – 38.0) | 0.814 |
 Hypertension (%, 95 % CI) | 67.0(66.3 – 67.7) | 53.0(50.3 – 55.7) | 68.2(67.5 – 68.9) | <0.001 |
 Previous smoking (%, 95 % CI) | 53.1(52.3 – 53.8) | 52.7(50.0 – 55.3) | 53.1(52.3 – 53.9) | 0.955 |
 Current smoking (%, 95 % CI) | 16.0(15.2 – 16.7) | 25.1(22.0 – 28.4) | 15.2(14.5 – 16.0) | <0.001 |
Pre-operative status | ||||
 NYHA classes III & IV (%, 95 % CI) | 43.7(42.9 – 44.4) | 53.7(51.0 – 56.4) | 42.8(42.0 – 43.6) | 0.351 |
 Atrial fibrillation (%, 95 % CI) | 19.3(18.7 – 19.9) | 40.5(37.9 – 43.2) | 17.4(16.8 – 18.0) | <0.001 |
 LVEF >45 % (%, 95 % CI) | 81.2(80.6 – 81.8) | 84.6(82.6 – 86.5) | 80.9(80.3 – 81.5) | 0.001 |
 LVEF 30 – 45 % (%, 95 % CI) | 12.1(11.6 – 12.6) | 10.9(9.3 – 12.7) | 12.2(11.7 – 12.7) | 0.154 |
 LVEF <30 % (%, 95 % CI) | 4.3(4.0 – 4.6) | 2.2(1.5 – 3.2) | 4.5(4.2 – 4.8) | <0.001 |
Previous procedures | ||||
 Valve surgery (%, 95 % CI) | 6.4(6.1 – 6.8) | 13.5(11.8 – 15.4) | 5.8(5.4 – 6.2) | <0.001 |
 Percutaneous balloon valvuloplasty (PBV) (%, 95 % CI) | 4.9(4.3 – 5.6) | 20.7(16.7 – 25.2) | 3.3(2.8 – 4.0) | <0.001 |